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 CD4+ T cells are essential for the effective functioning and appropriate regulation of the 
immune system. Antigen-naïve T cells require two distinct costimulatory signals to activate and 
differentiate into effector and memory T cells which can respond to antigen and direct the 
immune response. The first signal is through cognate antigen presented in major 
histocompatibility class II on an antigen-presenting cell binding to the T cell receptor. The 
second signal is the interaction of a costimulatory receptor on the T cell with a counter-receptor 
expressed on the antigen-presenting cell. This work focuses on the costimulatory receptors 
CD28, the classic T cell costimulatory molecule, and intercellular adhesion molecule-1 (ICAM-
1). ICAM-1 functions in adhesion and extravasation during inflammation, and our lab has 
previously published that ICAM-1 can function as a T cell second signal for activation. 
 Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contaminants 
which have been shown by many other investigators to have diverse effects on human health 
including the immune system. In the present work, we examined the consequences of exposure 
to two PAHs during naïve T cell costimulation. Bisphenol A, a widely used plasticizer and 
component of epoxy resins, was found to weakly promote naïve T cell proliferation during 
ICAM-1 costimulation but not in CD28 costimulation and did not perturb effector and memory 
cell differentiation in either costimulation. Pyrene, a product of incomplete combustion of 
organic materials, enhanced proliferation of naïve T cells in both ICAM-1 and CD28 
costimulations and inhibited effector and memory cell differentiation in both costimulations. 
 We also compared the differentiation of naïve T cells isolated using StemSep and 
EasySep naïve CD4+ T cell isolation kits upon being informed by StemCell, the manufacturer of 
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the kits, that StemSep was being discontinued in favor of EasySep. In contrast to StemSep naïve 
T cells, with which we have published previously, EasySep-purified naïve T cells did not 
differentiate in response to costimulation through ICAM-1 or CD28 without addition of 
exogenous cytokines and had dramatically increased cell death. We showed that inclusion of 
CD25 antibody in the EasySep negative selection antibody cocktail was partially responsible for 
the observed loss of differentiation and viability. Likewise, the EasySep magnetic beads were 
partially at fault for observed failure to differentiate and loss of viability in EasySep naïve T 
cells. This result also suggested an important role for the CD25lo population of naïve T cells in 
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  Chapter 1. Introduction 
 
 The immune system. The immune system has an innate branch and an adaptive branch. 
The innate branch is nonspecific and includes barrier defenses such as skin and mucosa. The 
adaptive branch recognizes and can remember specific threats. The adaptive branch consists of B 
cells, T cells, and antigen-presenting cells (APCs). B cells develop in the bone marrow and 
produce antibodies that bind to specific antigens and are responsible for humoral immunity. Pre-
T cells arise in the bone marrow and migrate to the thymus, where they develop into T cells, 
undergoing a selection process based on self/nonself recognition through the newly expressed T 
cell receptor (TCR).  
TCR/CD3 complex. The TCR is a specialized membrane receptor which can interact with 
only one specific, unique antigen (referred to as the cognate antigen). The TCR has two subunits, 
TCRα and TCRβ or TCRγ and TCRδ. The majority of T cells in the blood express TCRαβ, while 
cells bearing γδ TCRs make up less than 5% of T cells in the blood in humans and mice (1). 
However, most of the skin-resident T cells are γδ T cells. γδ T cells primarily respond to lipid 
antigens presented in CD1, while αβ T cells respond to peptide antigens presented within the 
major histocompatibility complex (MHC, known as HLA in humans). 
The TCR is always co-expressed with several accessory proteins known as CD3. The 
CD3 complex includes the εδ, γε, and ζζ dimers as well as TCRαβ or TCRγδ. CD3 is required to 
stabilize the TCR complex and to transduce signals across the membrane, as the TCR itself has 
extremely short cytoplasmic tails which cannot signal. CD3 signals via immunoreceptor 
tyrosine-based activation motifs (ITAMs) which consist of a YxxL/Ix6-8YxxL/I sequence. CD3 δ, 
ε, and γ each have one ITAM, while the ζ chains each possess 3 ITAMs, resulting in a total of 10 
ITAMs associated with each TCR complex. When the TCR binds to its cognate antigen, the 
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tyrosine residues in the ITAMs are quickly phosphorylated by kinases such as Lck, Fyn, ZAP-
70, Syk, Itk, and others. The phosphorylated ITAMs become docking sites for SH2 domain-
containing proteins, which propogate the signal downstream.  
 Mature T cells express either of the TCRαβ co-receptors CD8 or CD4. CD8+ T cells are 
also known as cytotoxic T cells because they recognize specific antigens presented in MHC class 
I and, when stimulated by cytokines, can kill target cells via the granzyme and perforin 
pathways. CD8+ T cells primarily target virus-infected cells. CD4+ T cells represent T helper 
cells or T regulatory cells. CD4+ T cells recognize antigen presented in MHC class II on APCs 
and produce cytokines which can direct the activity of other cells in an immune response. 
 Maturation of T cells in the thymus is considered primary lymphoid development. 95% of 
developing T cells die during this process of thymic selection. A T cell that survives thymic 
selection and leaves the thymus but has not yet encountered its cognate antigen is referred to as 
“naïve”. Naïve CD4+ T cells are classically defined as having the phenotype CD45RA+ RO(-) 
CD11a+ CD27lo CD62L+ CCR7+ (2-3), though recent studies indicate they are also CD25lo (4-5). 
Upon binding to the specific antigen that corresponds to a given cell’s TCR, the cell divides 
several times and undergoes a differentiation process. The factors that control the phenotypic 
outcome of naïve T cell differentiation are not entirely understood, although they appear to 
depend on the local cytokine milieu as well as specific receptor-mediated cell:cell contacts. This 
process is known as secondary lymphoid differentiation and occurs in the lymphoid follicles of 
the lymph nodes, spleen, and mucosal-associated lymphoid tissue. During this process, the cell 
becomes activated is referred to as a lymphoblast. After a number of clonal divisions, the cells 
differentiate into effector and memory cells. 
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 Effector CD4+ and CD8+ T cells have several possible roles in the immune response. 
Effector cells may secrete cytokines, chemokines, and other soluble factors that direct cells to 
become activated, to suppress other cells, to travel within the body, and to participate in the 
immune response. Most effector cells have a very short life in the body. After clearance of the 
target antigen, most effectors die via activation-induced cell death (AICD). However, a small 
number of cells survive after termination of the immune response, differentiating to memory 
cells. Memory T cells have long lifespans in the body and are able to respond very rapidly to 
repeat challenge with the same antigen. 
 However, in addition to occurring in the secondary lymphoid tissues, differentiation 
toward effector and memory phenotypes can also occur in tertiary lymphoid tissues (6). Tertiary 
lymphoid tissue consists of unencapsulated accumulations of lymphoid cells in locations other 
than the classical lymphoid organs. Tertiary lymphoid tissue bears organizational resemblance to 
lymph nodes and is thought to arise out of chronic inflammation related to non-resolving 
infection, autoimmune disease, cancer, and transplant rejection. Expression of the CCR7 ligand, 
CCL21, is sufficient to recruit naïve T cells into tertiary sites in mice and could play a role in 
naïve T cell recruitment in some human autoimmune diseases such as rheumatoid arthritis and 
ulcerative colitis (7). Once recruited to the tertiary site, the naïve T cells are retained by 
interaction through ICAM-1 or VCAM-1 on follicular dendritic cells or local stromal cells (8) 
and can receive differentiation signals. 
 Tertiary lymphoid tissue may have several alternative functions in the body. One role 
tertiary lymphoid tissue may serve is to control inflammation in the body. In artery tertiary 
lymphoid tissue, naïve CD4+ T cells can be induced to become Treg cells, which are protective 
in atherosclerosis (9). Alternatively, in systemic autoimmune diseases such as systemic lupus 
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erythematosus and rheumatoid arthritis, tertiary lymphoid tissue can generate autoreactive T 
cells, which are associated with more severe disease (10). Our understanding of the role of 
tertiary lymphoid tissue in the body in health and disease is clearly still evolving. 
 Naïve T cell differentiation. Naïve CD4+ T cells require two distinct signals for 
differentiation to occur, a signal through the TCR from the binding of cognate antigen presented 
in MHC and a signal through a costimulatory receptor on an APC. The classic T cell second 
signal is through CD28, although other costimulatory receptors exist including ICAM-1 (11), 
CTLA-4 (12), CD5 (13), and CD27 (14). Our lab has shown stimulating naïve CD4+ T cells 
through the TCR as well as CD28 in the absence of exogenous cytokines promotes 
differentiation to T helper 1 (Th1) and T helper 2 (Th2) phenotypes but not T regulatory (Treg) 
cell phenotype (15). Conversely, stimulation through the TCR as well as ICAM-1 promotes 
differentiation to Th1 and Treg cells in the absence of exogenous cytokines but not Th2 cells 
(16), while stimulation through the TCR + CTLA-4 promotes differentiation to Treg through a 
different pathway than used by ICAM-1 costimulation (12). If only signal one is received, the 
cell will enter an unresponsive state known as anergy and ultimately die by apoptosis.  
 T cell subsets. There are many possible outcomes of CD4+ T cell differentiation (Figure 
1.1), with new phenotypes still being discovered. T helper 1 cells secrete proinflammatory 
cytokines such as interferon-γ and interleukin-12, activating cytotoxic T cells and macrophages 









Figure 1.1 Diagram depicting some of the many potential phenotypic outcomes of naïve 
CD4+ T cells. The naïve CD4+ T cell (center, dark blue) may differentiate into a Th1 cell (right, 
red), Th2 cell (bottom, green), Th17 cell (lower left, orange), Treg cell (light blue, upper left), or 
a Th9 cell (upper right, yellow) depending on the specific costimulatory signals received by the 
naïve cell as well as the local cytokine environment.   
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factor T-bet. T helper 2 cells can be identified by expression of the transcription factor Gata3 and 
secrete interleukin-4 and interleukin-10, providing B cell help in situations of free-living 
bacteria, parasites, and playing a role in allergic reactions. T regulatory cells are characterized by 
expression of CD25, the high affinity IL-2 receptor (IL-2Rγ), as well as the other components of 
the IL-2 receptor and the transcription factor FoxP3, and they secrete interleukin-10 and TGF-β, 
which are generally suppressive cytokines.  
 The more recently discovered CD4+ T cell phenotypes include T helper 17 cells and T 
helper 9 cells. T helper 17 cells are potent proinflammatory cells which secrete interleukin-17 
and interleukin-23 and express the transcription factor RORγt. T helper 9 cells secrete 
interleukin-9, which stimulates cell proliferation in several hematopoietic cell types, as well as 
interleukin-10, and they express the transcription factor Gata3 (17). 
 ICAM-1. ICAM-1 (Intercellular adhesion molecule-1), also known as CD54, has five 
extracellular Ig domains which are glycosylated and contain disulfide bridges as well as a 
transmembrane domain followed by a short 28 amino acid cytoplasmic domain. The cytoplasmic 
domain has a single tyrosine residue which can be phosphorylated and is conserved among 
human, mouse, and rat (18). In addition, the cytoplasmic domain of ICAM-1 contains an SH3 
binding domain and many positively-charged residues which could serve in recruiting and 
binding signal proteins (19). However, it is important to note that the SH3 binding domain is not 
conserved in murine or hamster ICAM-1 sequences (15), which could indicate that this domain 
is not functionally significant or that ICAM-1 functions differently among species. 
 The primary counter-receptor of interest of ICAM-1 with respect to T cell biology is 
integrin LFA-1 (αLβ2 or CD11a/CD18). LFA-1 on leukocytes binds to ICAM-1 on inflamed 
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tissue, playing a key role in the extravasation of immune cells. Additionally, ICAM-1 is used for 
attachment or entry by several pathogens, such as rhinovirus and Plasmodium falciparum-
infected erythrocytes (20). ICAM-1 exists in native membrane-bound form as a non-covalent 
dimer, and dimerization correlates with dramatically enhanced binding of LFA-1 (18). ICAM-1 
is widely expressed in the body, including endothelial cells, epithelial cells, fibroblasts, 
astrocytes, and leukocytes. On naïve and resting T lymphocytes, ICAM-1 is expressed at low 
levels but is upregulated on activation (21). Additionally, ICAM-1 can serve as a costimulatory 
molecule for T cells (11, 22). 
 The cytoplasmic domain of ICAM-1 is only 28 aa in human and lacks any catalytic 
activity. One study using rat T cells expressing truncated human ICAM-1 showed that the 
intracellular domain of ICAM-1 was essential for transendothelial migration, indicating a critical 
role for ICAM-1 signaling in T cells (16). Our lab has published the only extant data on the 
ICAM-1 signaling pathway in T cells in which we demonstrated that the cyclin dependent kinase 
cdc2 becomes transiently phosphorylated upon ICAM-1 crosslinking, and this phosphorylation 
correlates with inhibition of cdc2 activity in primary human T cells (23). However, studies in T 
cells as well as several other cell types suggest that ICAM-1 signals into the cell. Cortactin is 
time-dependently phosphorylated on tyrosine upon crosslinking of ICAM-1 in a rat endothelial 
cell line (24). Likewise, Lyn becomes phosphorylated on tyrosine in a mouse B cell lymphoma 
line when stimulated through ICAM-1 (25). p38 MAPK, ERK, and MKK3/6 are inducibly 
phosphorylated when stimulated through ICAM-1 in human airway epithelial cells (26). ICAM-1 
associates with the actin cytoskeleton (27), most likely via interaction with ezrin (28-29). 
 CD28. CD28 is a membrane-bound, disulfide-linked glycosylated homodimer known as 
the prototypical T cell costimulatory receptor. CD28 is expressed on nearly all CD4+ T cells and 
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most CD8+ T cells (30). Unlike ICAM-1, CD28 has a single extracellular Ig variable-like 
domain. Its primary counter-receptors are B7-1 and B7-2, which are expressed on activated 
APCs. CD28 has a cytoplasmic YMNM consensus sequence which acts as a binding site for p85 
of PI3K as well as Grb2 (31). CD28 also has a cytoplasmic PxxP motif which can be bound by 
SH3 domain-containing proteins (31). 
 This thesis. This thesis will investigate the potential effects on human health of the 
polycyclic aromatic hydrocarbons (PAHs) bisphenol A and pyrene on human naïve CD4+ T cell 
differentiation, with emphasis on effector and memory cell differentiation, Th1/Th2/Treg 
differentiation, proliferation and cell death. Additionally, the thesis will compare two methods 
for naïve CD4+ T cell isolation with respect to differentiation outcome and viability. Finally, I 
will briefly summarize my evaluation of peptides corresponding to the ICAM-1 binding domain 
for potential treatment of equine recurrent uveitis (ERU), identification of human T cell proteins 
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PAHs. Polycyclic aromatic hydrocarbons (PAHs) are compounds primarily produced 
during combustion of organic matter. Humans are exposed to PAHs in the form of car exhaust, 
cigarette smoke, plastics, grilled foods, and many others. PAH exposure has been linked to a 
wide variety of human diseases, including asthma, autoimmune diseases, leukemia, obesity, 
cardiovascular disease, and cancers (1-6). PAHs are hydrophobic and readily pass through cell 
membranes (7). 
 We chose to evaluate the effects of two specific PAH compounds on human T cell 
immunology. Those compounds are bisphenol A (BPA, alternatively known as 4,4’-
isopropyllidenediphenol) and pyrene (benzo[def]phenanthrene). 
BPA. BPA has two unconjugated phenolic rings (see Figure 2.1). Determining the effects 
of BPA on humans is of interest because BPA is becoming nearly ubiquitous in the environment, 
and its presence there is entirely due to anthropogenic activity, as BPA does not naturally occur. 
In fact, in 2007 the United States alone produced 5.3 billion kg of BPA, commercially valued at 
$2 billion (8). BPA is used as a raw material in the production of a wide variety of commercial 
products. 95% of all BPA produced is used to make polycarbonate plastic and epoxy resin. 
Products containing BPA include water bottles, coatings of food and beverage cans, CDs and 
DVDs, children’s toys, food storage containers, tableware, medical devices, baby bottles, dental 















BPA is detectable at varying levels in air, water, and soil around the world, particularly 
near industrial manufacturing centers and landfills. However, the primary route of human 
exposure is dietary. It is thought that the principal sources of dietary BPA are canned foods lined 
with epoxy resins, drinking water in polycarbonate bottles, and saliva from individuals who have 
dental sealants and composites. BPA is metabolized in the liver or intestine and excreted through 
the kidneys with a half-life of 6 or more hours for orally ingested BPA (9-10). However, humans 
are continuously exposed to BPA, and BPA has been shown to partition to lipid-rich tissues, 
resulting in chronic exposure (11-13).  
Data suggest BPA may affect humans by acting as an endocrine disruptor, a potential 
carcinogen, and a promoter of obesity and cardiovascular disease. 
A large body of research supports the hypothesis that BPA can behave as an endocrine 
disruptor in humans. BPA is an agonist for human estrogen receptors as well as an antagonist for 
human androgen receptors (14), suggesting potential mechanisms for the observed endocrine 
disrupting effects of BPA. These effects include consistently higher rates of all types of sexual 
dysfunction in BPA-exposed male workers compared to unexposed workers (15). Further, BPA 
exposure is associated with earlier onset of puberty in males (16), and human testes treated with 
BPA ex vivo had significantly decreased testosterone production in a dose-dependent fashion 
(17). 
BPA may also affect human reproduction. Serum BPA levels of the male partners of 
women undergoing in vitro fertilization are inversely correlated with embryo quality (18). 
Likewise, serum BPA levels in women undergoing in vitro fertilization inversely correlate with 
rate of fertilization; doubling of serum BPA level was associated with 55% decrease in the 
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probability of fertilization (19). One meta-analysis found that BPA directly negatively affects 
birthweight, preterm birth rates, developmental defects, and recurrent miscarriage in humans 
(20). 
BPA exposure may also cause certain cancers. Early-life exposure to BPA seems to 
increase cancer risk in later life. For instance, fetal treatment of rats with BPA was associated 
with mammary carcinomas in up to 33% of adult rats (21). Another study found that fetal 
exposure to BPA was strongly associated with development of mammary carcinomas (22). These 
carcinomas were very large (>1 cm in diameter), and the serum levels of BPA in these rats was 
comparable to serum BPA levels observed in humans. Further, the association of BPA exposure 
with development of cancer is not limited to animal studies nor to mammary tissue cancers. One 
study of 60 urology patients showed a correlation between creatinine-adjusted urinary BPA 
levels and biopsy-confirmed prostate cancer, a link which was more pronounced in men younger 
than 65 years of age (23). 
 BPA exposure is further associated with obesity, both in humans as well as in rodent 
models. A large Canadian study of 4733 adults revealed a positive correlation with urinary BPA 
level and obesity defined by body mass index as well as increased waist circumference (24). 
Similarly, a meta-analysis of 61 rodent studies found significant positive associations between 
fetal BPA exposure and fat pad weight, triglyceride levels, and free fatty acids (25). Stronger 
positive associations were observed for male rodents as well as at BPA exposures below the US 
FDA reference dose of 50 μg/kg of body weight per day.  
 Data further suggest a relationship between BPA exposure and cardiovascular disease. In 
humans, both urinary (26) and serum (27) BPA levels are positively associated with 
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hypertension. Urinary BPA levels are also positively associated with cardiovascular diseases 
such as coronary heart disease, myocardial infarction, and angina (28-30). 
 Data on the effects of BPA in the immune system are somewhat variable. Prenatal BPA 
exposure may affect mice differently than adult exposure. BPA promotes T helper 1 immune and 
T helper 2 responses in prenatally exposed mice (31-32), while adulthood BPA exposure 
enhanced T helper 2 responses but not T helper 1, with a reduction in the percentage of CD4+ 
CD25+ cells (32). However, other groups found the BPA treatment of adult mice enhanced T 
helper 1 responses (33-35). Some studies found that BPA treatment increased splenocyte 
proliferation induced by the lymphocyte mitogen concanavalin A (35-36), while others report 
reduction in concanavalin A-induced splenocyte proliferation (33). One study in rats observed 
that perinatal BPA exposure was associated with severe colonic inflammation, a T helper 1 type 
response, which occurred in female rats only (37), while urinary BPA levels in humans correlate 
with childhood asthma, a T helper 2 dominated pathology (38). These disparate results suggest 
that further study on the influence of BPA on the immune system, particularly in humans is 
needed.  
 Pyrene. Pyrene is a peri-condensed PAH with four conjugated aromatic rings (see Figure 
2.2). Pyrene is used in the manufacture of pesticides, dyes, and plastics, but it is also produced 
during incomplete combustion reactions such as the combustion of gasoline in an automobile 
engine, burning of wood and coal for heating and cooking, and burning of tobacco in cigarettes. 
Most human exposure to pyrene is via inhalation of air pollution in cities, including car exhaust, 
and wood, coal, or cigarette smoke, but occupational exposure and exposure through 
consumption of grilled or charred meat or other foods can also contribute.  
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 Little is known concerning the effects of pyrene specifically on the human body, as the 
overwhelming majority of research conducted on pyrene-exposed cells or organisms employed a 
mixture of PAHs including pyrene rather than pyrene alone.  Pyrene is thought to be involved in 
estrogen signaling, but its precise role is not clear (39). One study showed immunized mice 
treated with pyrene had enhanced antigen-induced IgE production, and splenic lymphocytes from 
the immunized mice had increased secretion of IL-4 when treated with pyrene in vitro (40). Both 
IgE and IL-4 are associated with a T helper 2 and allergic response. Similar results with respect 
to IgE production were obtained using pyrene-treated mice immunized with different allergens 
(41-43). Additionally, human peripheral blood mononuclear cells and peripheral T cells 
stimulated with concanavalin A exhibited dose-dependent increase in IL-4 protein and mRNA 
synthesis when treated with pyrene (43), further supporting the hypothesis that pyrene promotes 
a T helper 2/allergic type immune response. One additional study demonstrated that pyrene-
treated primary human fibroblasts had enhanced production of IL-8 mRNA and protein (44). IL-
8 is the chemokine CXCL8, which is known as an attractor and activator of neutrophils but may 
also play a role in airway inflammation because IL-8 can be produced by airway smooth muscle 
cells, among other cell types. 
 This chapter. Here we have isolated human CD4+ naïve T cells from donated peripheral 
blood and treated them with BPA, pyrene, or DMSO during costimulation through CD28 or 
ICAM-1 to determine the effects of these compounds on differentiation outcome. We measured 





Materials and methods 
 
Antibodies and reagents  
 Anti-CD3 (clone OKT3) was purchased from eBioscience (San Diego, CA), anti-CD28 
(clone CD28.2) was purchased from BioLegend (San Diego, CA), and anti-ICAM-1 (clone R6.5) 
was purchased from BioXCell (West Lebanon, NH). Annexin V-PE, 7-Amino-Actinomycin D 
(7AAD), and anti-CD25-FITC (clone M-A251) were purchased from BD Pharmingen (San Jose, 
CA). Anti-CD11a-FITC (clone MEM-25) was purchased from Novus Biologicals (Littleton, 
CO), anti-CD27-PE (clone O323) was purchased from eBioscience (San Diego, CA), and anti-
CD45RO-PerCP (clone UCHL1) was purchased from Invitrogen (Camarillo, CA). Anti-FoxP3-
APC (clone 3G3) was purchased from Miltenyi Biotec (San Diego, CA). The isotype control was 
mouse IgG1-APC (eBioscience clone P3) for the FoxP3 antibody. The transcription factor 
staining buffer set for flow cytometry was purchased from eBioscience (San Diego, CA). 
 BPA (97% pure) was purchased from Sigma-Aldrich (St. Louis, MO) and aseptically 
dissolved in sterile DMSO (MP Biomedicals; Santa Ana, CA) at 0.3 mg/ml then diluted in 
DMSO to 3 μg/ml. 2 μL of 3 μg/ml BPA was added to the 200 μL total tissue culture well 
volume for final well concentration of 30 ng/ml BPA. Reagent-grade pyrene was purchased from 
Sigma-Aldrich (St. Louis, MO) and dissolved aseptically in sterile DMSO at 0.1 mg/ml, diluted 
in DMSO to 1 μg/ml, then 2 μl of 1 μg/ml pyrene was added to the tissue culture well of 200 μl 
total volume for a final concentration of 10 ng/ml pyrene. For the DMSO control, 2 μl neat 
sterile DMSO was added to each tissue culture well (total volume 200 μl). 
Naïve T cells are primarily located in the blood and the lymphatics in vivo, so to 
determine how much BPA or pyrene to treat the naïve T cells with during the differentiation 
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experiments we examined the serum BPA and pyrene levels reported in the literature. The 
highest BPA levels are found in infants and children, but our blood donors were adults so we 
investigated published serum BPA levels from adults. BPA levels varied somewhat among 
individuals, investigations, men and women, and detection methods, ranging from below the 
limit of detection to 67.4 ng/ml (27, 45-49). However, the median serum level of BPA in adults 
in all studies here examined was approximately 1-3 ng/ml. Therefore, we chose to treat the naïve 
T cells with 30 ng/ml BPA for this project.  
 Serum measures of pyrene exposure in humans are very limited. No differences in serum 
pyrene levels has been observed between adults and children (unlike BPA), so we decided to 
include pyrene levels from children in our consideration. One study in adults found the mean 
level of pyrene in the serum to be 0.3 ng/ml (7) The only other serum pyrene level reported in the 
literature was a mean value of 1.1 ng/ml in sera from asthmatic children (50). Based on this 




 Heparinized peripheral whole blood (240 ml) was collected from healthy volunteer 
donors and diluted two parts blood into one part sterile TC-PBS (137 mM NaCl, 2.7 mM KCl, 
1.5 mM KH2PO4, 9.6 mM Na2HPO4, 0.7 mM CaCl2, 0.5 mM MgCl2, and 10 mM glucose, pH 
7.4) + 2% FBS + 1% penicillin/streptomycin. The PBMC layer was separated using Ficoll 
density gradient centrifugation, collected by pipette, washed in TC-PBS to remove residual 
Ficoll and platelets, and counted using a hemocytometer. The total yield of PBMC were further 
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purified to naïve CD4+ T cells using the StemSep kit (cat#14155; StemCell, Vancouver, BC, 
Canada) according to the manufacturer. Purity was immediately assessed for each isolation by 
staining for CD11a, CD27, and CD45RO and analyzing by flow cytometry, gating on CD11a+ 
CD27lo CD45RO(-) population. 
 
Cell stimulation 
 Stimulating antibodies were diluted in sterile PBS to titrated lowest effective 
concentration. OKT3 (anti-CD3) was used at 1 μg/ml with either CD28.2 (anti-CD28) at 2 μg/ml 
or R6.5 (anti-ICAM-1) at 10 μg/ml. Antibody solutions were added to 96-well tissue culture-
treated plates (TPP, Switzerland) and incubated for 2 hours at 37°C or overnight at 4°C. Wells 
were then washed 3X with sterile PBS to remove any unbound antibody. Cells were added to the 
wells at 1.5×106 cells/ml in RPMI 1640 (CellGro; Corning, New York) with 10% heat-
inactivated fetal bovine serum (Atlanta Biologicals, Atlanta, GA), 50 IU/ml penicillin/50 μg/ml 




 Cells were removed from the tissue culture plate by gentle pipetting. Cell proliferation 
was measured by CFSE dilution as we have previously described (51). Cells were labeled prior 
to stimulation using 2.5 μM 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE: 
Molecular Probes; Eugene, OR) from 5 mM stock solution in DMSO for 7 minutes at 37°C in 
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serum-free RPMI 1640. For cell death stain, cells were washed twice in cold PBS, stained in 
Annexin V binding buffer (0.01 M HEPES pH 7.4, 0.14 M NaCl, 2.5 mM CaCl2) with Annexin 
V-PE (BD Pharnimgen, San Jose, CA) and 7AAD (7-aminoactinomycin D; BD Pharmingen), 
and washed once in Annexin V binding buffer prior to flow cytometry analysis. For all other 
stains, cells were blocked with 0.5% BSA in PBS for 15 minutes on ice, stained with fluorescent-
tagged antibodies against cell surface targets for 1 hour in ice in the dark, washed once in cold 
PBS, and analyzed by flow cytometry. For evaluation of effector and memory differentiation, 
cells were stained with CD11a-FITC, CD27-PE, and CD45RO-PerCP. For transcription factor 
stains, cells were blocked and stained for surface targets first, then fixed, permeabilized, and 
stained for transcription factors using eBioscience transcription factor staining buffer kit. The 
Treg stain was anti-FoxP3-PE with anti-CD25-PECy5. Stained cells were then analyzed 
immediately using the Accuri C6 flow cytometer with CFlow software (Accuri Cytometers). 




 GraphPad Prism software (GraphPad Software version 8.2.0, La Jolla, CA) was used to 








 Due to unforeseen difficulties in cell purification (see Chapter 3) we were unable to 
obtain sufficient n values for some experiments. As such, these data are considered preliminary. 
 
 
Treatment of human naïve CD4+ T cells with BPA or pyrene during costimulation did not 
cause toxicity at Day 7. 
The initial goal of this project was to establish whether BPA or pyrene would cause 
toxicity in naïve CD4+ T cells at the experimental dosages during costimulation. Our lab 
routinely evaluates cell death by staining cells using fluorochrome-tagged Annexin V and 7-
aminoactinomycin D (7AAD) as we have published previously (52). Annexin V is a protein that 
binds the cell membrane phospholipid phosphatidylserine. Phosphatidylserine is normally found 
only on the inner leaflet of the cell membrane but during the loss of membrane asymmetry that 
occurs during apoptosis, phosphatidylserine becomes exposed on the outer membrane leaflet. 
Using fluorochrome-labeled Annexin V, apoptosis can be sensitively detected in this way via 
flow cytometry. 7AAD is a fluorescent molecule which binds nucleic acids but does not pass 
through cell membranes. Dead and dying cells undergo loss of membrane integrity, causing their 
nucleic acids to be exposed and accessible by 7AAD. Cells which stain positively for both 
Annexin V and 7AAD are dead, while double negative cells are viable. 
We investigated the number of dead cells using Annexin V/7AAD co-staining after 
treating naïve CD4+ T cells with 30 ng/ml BPA, 10 ng/ml pyrene, or DMSO vehicle for 7 days 
during costimulation through ICAM-1 or CD28. Figure 2.3 illustrates cell death during ICAM-1 
costimulation for DMSO, BPA, or pyrene treated cells. The number of dead (Annexin V+ 
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Figures 2.3-2.4. BPA and pyrene did not significantly affect apoptotic cell death during 
ICAM-1 costimulation of naïve CD4+ T cells. Naïve CD4+ T cells were stimulated through 
CD3+ICAM-1 in the presence of BPA, pyrene, or DMSO vehicle control for 7 days then stained 
with Annexin V and 7AAD and analyzed using flow cytometry. 2.3 Representative dot plots 
showing apoptosis stain with apoptotic cells in UR quadrant. Percent of apoptotic cells (Annexin 
V+ 7AAD+) given in bold, with number of apoptotic cells in parentheses. 2.4 Number of 
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Figures 2.5-2.6. BPA was protective against cell death while pyrene did not significantly 
affect apoptotic cell death during CD28 costimulation of naïve CD4+ T cells. Naïve CD4+ T 
cells were stimulated through CD3+CD28 in the presence of BPA, pyrene, or DMSO vehicle 
control for 7 days then stained with Annexin V and 7AAD and analyzed using flow cytometry. 
2.5 Representative dot plots showing apoptosis stain with apoptotic cells in UR quadrant. Percent 
of apoptotic cells (Annexin V+ 7AAD+) given in bold, with number of apoptotic cells in 
parentheses. 2.6 Number of apoptotic cells after 7 days of costimulation with error bars 




cells found in the DMSO vehicle control (Figure 2.4). For BPA, p=0.45 while for pyrene p=0.12 
by paired two-tailed students t test. 
Figure 2.5 depicts the number of dead cells during CD28 costimulation of DMSO, BPA, 
and pyrene treated naïve T cells. Treatment with BPA actually resulted in significantly fewer 
dead cells compared to the DMSO vehicle control (p<0.05 by paired two-tailed t test; Figure 
2.6) while pyrene treatment did not significantly influence number of dead cells compared to 
DMSO control (p=0.61; Figure 2.6). 
 
BPA and pyrene may promote proliferation of naïve CD4+ T cells during CD28 and 
ICAM-1 costimulation. 
Cell proliferation is an essential part of naïve T cell differentiation, and existing data on 
the effects of PAHs on proliferation is conflicting. As such, it was of interest to evaluate the 
influence of BPA and pyrene on naïve T cell proliferation.  
Cell proliferation can be measured by staining the cells with the CFSE, which readily 
passes through the cell membrane and is crosslinked to intracellular proteins, becoming 
fluorescent when cleaved by the cell’s esterases. Each time the cell divides, the dye is partitioned 
into the two daughter cells, becoming more dilute with each division. The fluorescence of the 
proliferating cells is then measured using a flow cytometer, with a fluorescence peak visible for 











Figure 2.8  
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Figures 2.7-2.8. BPA or pyrene may promote cell proliferation during ICAM-1 
costimulation of naïve CD4+ T cells. Naïve CD4+ T cells were stained with CFSE then 
stimulated through CD3+ICAM-1 in the presence of BPA, pyrene, or DMSO vehicle control for 
7 days and analyzed using flow cytometry. 2.7 Representative CFSE histograms showing 
percentage of proliferated cells in bold above the gate; number of proliferated cells is given in 
parentheses. Representative of 2 experiments. 2.8 Number of proliferated cells after 7 days of 














Figures 2.9-2.10. Exposure to pyrene during CD28 costimulation may promote cell 
proliferation. Naïve CD4+ T cells were stained with CFSE then stimulated through CD3+CD28 
in the presence of BPA, pyrene, or DMSO vehicle control for 7 days and analyzed using flow 
cytometry. 2.9 Representative CFSE histograms showing percentage of proliferated cells in bold 
above the gate; number of proliferated cells is given in parentheses. Representative of 2 
experiments. 2.10 Number of proliferated cells after 7 days of costimulation with error bars 




Figure 2.7 shows representative CFSE histograms for naïve T cells treated with DMSO, 
BPA, or pyrene after 7 days of ICAM-1 costimulation. These preliminary data suggest a small 
increase in number of proliferated cells during BPA treatment compared to the DMSO vehicle  
control, with a more dramatic increase in proliferation resulting from pyrene treatment compared 
to DMSO control (Figure 2.8). However, it should be noted that n=2 for this experiment. 
Number of proliferated naïve T cells during BPA, pyrene, and DMSO treatment after 7 
days of CD28 costimulation is given in Figure 2.9. These preliminary data (n=2 due to loss of 
ability to isolate functional naïve T cells) suggest that BPA treatment did not affect the number 
of proliferated cells in CD28 costimulation and that pyrene may have increased the number of 
divided cells compared to the DMSO control (Figure 2.10).  
 
Pyrene may reduce differentiation of effector and memory cells during ICAM-1 and 
CD28 costimulation of naïve T cells. 
A critical step of elucidating any effects of BPA and pyrene exposure on naïve CD4+ T 
cell differentiation and the overall immune response is measuring differentiation of the effector 
and memory cell populations during costimulation. To assess the effector and memory 
populations, we first gated on the CD45RO+ population, removing any remaining 
undifferentiated naïve cells from the analysis. Then we evaluated CD11a and CD27 expression. 
Naïve T cells start out in the upper left quadrant, CD11a(-) CD27+. As they differentiate into 
effector cells, they migrate into the upper right quadrant, becoming CD11a+ CD27+. Finally, 
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Figures 2.11-2.13. Exposure to pyrene during ICAM-1 costimulation may reduce effector 
and memory cell differentiation. Naïve CD4+ T cells were stimulated through CD3+ICAM-1 
in the presence of BPA, pyrene, or DMSO vehicle control and analyzed using flow cytometry at 
Day 7 and Day 14. 2.11 Representative flow cytometry dot plots gated on CD45RO+ 
(differentiated) population showing percentage of effector cells (CD45RO+ CD11a+ CD27+) in 
bold with number of effector cells in parentheses in the UR quadrant. Memory cells are shown in 
the LR quadrant (CD45RO+ CD11a+ CD27(-)) with percentage of memory cells in bold and 
number of memory cells in parentheses. 2.12 Number of effector cells after 7 (left) or 14 (right) 
days of costimulation with error bars indicating standard error; n=5-6 (Day 7) or n=3-5 (Day 14). 
2.13 Number of memory cells after 7 (left) or 14 (right) days of costimulation with error bars 
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Figures 2.14-2.16. Exposure to pyrene during CD28 costimulation reduces effector and 
memory cell differentiation at Day 14. Naïve CD4+ T cells were stimulated through 
CD3+CD28 in the presence of BPA, pyrene, or DMSO vehicle control and analyzed using flow 
cytometry at Day 7 and Day 14. 2.14 Representative flow cytometry dot plots gated on 
CD45RO+ (differentiated) population showing percentage of effector cells (CD45RO+ CD11a+ 
CD27+) in bold with number of effector cells in parentheses in the UR quadrant. Memory cells 
are shown in the LR quadrant (CD45RO+ CD11a+ CD27(-)) with percentage of memory cells in 
bold and number of memory cells in parentheses. 2.15 Number of effector cells after 7 (left) or 
14 (right) days of costimulation with error bars indicating standard error; n=6-7 (Day 7) or n=6 
(Day 14). 2.16 Number of memory cells after 7 (left) or 14 (right) days of costimulation with 





























We measured effector and memory cell differentiation during treatment with BPA, 
pyrene, or DMSO vehicle at 7 and 14 days of costimulation. Figure 2.11 consists of 
representative dot plots gated on CD45RO+ populations showing effector and memory 
populations of ICAM-1 costimulated naïve T cells at Day 7 (top row) and Day 14 (bottom row).  
We observed that BPA and pyrene treatment had no impact on effector differentiation at Day 7 
(Figure 2.12, left) but at Day 14, pyrene may have caused a non-significant reduction in effector 
cell numbers (Figure 2.12, right). Similarly, there was no effect on memory cell numbers 
(Figure 2.13) at Day 7 by either BPA or pyrene though at Day 14, the data suggest a non-
significant reduction in memory cell number during ICAM-1 costimulation. 
In Figure 2.14, we display CD11a versus CD27 dot plots gated on CD45RO+ cell 
population of naïve T cells treated with BPA, pyrene, or DMSO during CD28 costimulation. 
BPA treatment did not influence number of effector cells at Day 7 or Day 14 (Figure 2.15). 
However, pyrene treatment may have non-significantly increased the number of effector cells at 
Day 7 though by Day 14 the number of effector cells was significantly lower for pyrene 
treatment compared to DMSO (Figure 2.15, p<0.05 by paired two-tailed t test). Likewise, BPA 
treatment did not alter the number of memory cells at Day 7 or Day 14 (Figure 2.16). Pyrene 
treatment may have non-significantly enhanced the number of memory cells present at Day 7; 
however the number of memory cells was significantly reduced for pyrene treatment at Day 14 






Pyrene may inhibit differentiation of T regulatory cells during ICAM-1 costimulation. 
Because we found that PAHs influenced effector and memory differentiation of naïve T 
cells, we wanted to evaluate the effects of these PAHs on differentiation of the CD4+ T cell 
subsets. Differentiation of T regulatory cells is a major area of focus for our laboratory so 
naturally we investigated the effects of the PAHs on Treg differentiation. The standard method 
of evaluating T regulatory cell number is by staining the cells for the transcription factor FoxP3 
and for CD25. T regulatory cells are FoxP3+ CD25+.  
We measured differentiation of T regulatory cells from naïve CD4+ T cells treated with 
BPA, pyrene, or DMSO after 10-12 days of ICAM-1 or CD28 costimulation. Representative dot 
plots with T regulatory cells in the upper right quadrant indicate number of T regulatory cells 
during ICAM-1 costimulation (Figure 2.17). We observed that BPA did not alter the number of 
T regulatory cells, but pyrene may have reduced the number of T regulatory cells differentiated 
(Figure 2.18). These preliminary data suggested that BPA and pyrene did not perturb T 











       n=2-3 
42 
 
Figure 2.17-18. Exposure to pyrene during ICAM-1 costimulation may inhibit 
differentiation of Treg cells. Human naïve CD4+ T cells were stimulated through CD3+ICAM-
1 for 10-12 days in the presence of BPA, pyrene, or DMSO vehicle control then analyzed by 
flow cytometry for CD25 and FoxP3 expression. 2.17 Representative flow cytometry dot plots 
with Treg cells (FoxP3+ CD25+) shown in UR quadrant with percentage in bold and cell number 
in parentheses. 2.18 Graph shows mean number of Treg cells differentiated during ICAM-1 
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Figure 2.19-20. Treg differentiation during CD28 costimulation was not significantly 
affected by exposure to BPA or pyrene. Human naïve CD4+ T cells were stimulated through 
CD3+CD28 for 10-12 days in the presence of BPA, pyrene, or DMSO vehicle control then 
analyzed by flow cytometry for CD25 and FoxP3 expression. 2.19 Representative flow 
cytometry dot plots with Treg cells (FoxP3+ CD25+) shown in UR quadrant with percentage in 
bold and cell number in parentheses. 2.20 Graph shows mean number of Treg cells differentiated 








 BPA and pyrene are ubiquitous in the human environment and exposure has been shown 
to have diverse consequences for human health, including the immune system. However, the 
effects of BPA and pyrene on human CD4+ naïve T cell differentiation have yet to be 
determined. In the present work, we examined the effects of biologically relevant doses of BPA 
and pyrene on human naïve T cell proliferation and differentiation during costimulation. 
 We first verified that the experimental doses of BPA and pyrene were not toxic to naïve T 
cells during costimulation. We observed that 30 ng/ml BPA or 10 ng/ml pyrene did not affect 
cell death during ICAM-1 costimulation, but during CD28 costimulation, BPA reduced cell 
death while pyrene did not influence cell death. Therefore, we concluded that these levels of 
BPA and pyrene were not toxic to naïve T cells after 7 days of exposure. 
 Next, we investigated the effects of BPA and pyrene on naïve T cell proliferation as 
proliferation is a critical part of the naïve T cell differentiation process. Preliminary results 
suggested that BPA may have promoted a modest increase in proliferation during ICAM-1 
costimulation but not CD28 costimulation, while pyrene may have promoted proliferation in 
both ICAM-1 and CD28 costimulations. 
 One method of evaluating effects on naïve T cell differentiation was to measure the 
effector and memory cell populations after 7-14 days of costimulation. We found that BPA 
treatment did not influence the number of effector or memory cells differentiated after 7 or 14 
days of costimulation through ICAM-1 or CD28. However, pyrene treatment significantly 
reduced effector and memory cell numbers at Day 14 for CD28 costimulation only. 
46 
 
 To further clarify the effects of BPA and pyrene on naïve T cell differentiation, we 
measured T regulatory cell differentiation in the presence of BPA or pyrene. Our preliminary 
results suggested that BPA did not affect Treg formation in ICAM-1 or CD28 costimulation but 
pyrene may have reduced Treg cell differentiation in the ICAM-1 costimulation only. 
 These data do not support a dramatic effect by BPA on human naïve T cell 
differentiation. There are many possible explanations for this result. One potential interpretation 
is that the DMSO control may also have been exposed to BPA through leaching from plastic 
pipet tips as well as the polystyrene tissue culture plate. Significant leaching of BPA from 
various plastics has been shown to occur at room temperature and 37°C (53). This leaching could 
have effectively caused all wells including the vehicle control to be exposed to enough BPA that 
we were unable to detect any effects of BPA treatment because the level of effective BPA 
exposure for the control and the BPA treatment were too similar. 
 Another possibility is that BPA has sex-specific effects. BPA is an estrogen agonist as 
well as an androgen antagonist (14), suggesting a potential avenue for sex-specific effects. 
Likewise, many studies in humans, mice, rats, and sheep have observed effects of BPA exposure 
which occurred only in females or only in males (4, 27, 37, 54-58). If any sex-specific BPA 
effects occurred in the present study, they may not be detectable here due to small experimental 
size. 
 The data for pyrene treatment suggested that pyrene may have promoted naïve T cell 
proliferation but inhibited differentiation to effector and memory cells and potentially also T 
regulatory cells. These observations do not easily reconcile with existing data on naïve T cell 
responses, though additional n values may clarify these observations. Further, while pyrene 
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inhibited effector and memory cell differentiation, it is unlikely to have induced anergy because 
the pyrene-treated cells had increased proliferation compared to the vehicle control, and anergic 
T cells do not proliferate or secrete IL-2, though they do express IL-2 receptors and respond to 
exogenous IL-2. Further studies involving measurement of IL-2 secretion, IL-2 receptor 
expression, and addition of IL-2 to pyrene-treated naïve T cells may help to illuminate the effects 
of pyrene with respect to anergy.  
 Another avenue of exploration would be to further characterize the population of 
proliferating but non-differentiating pyrene-treated naïve T cells. Of particular interest would be 
determining if pyrene-treated cells continue to express naïve T cell markers beyond 
CD45RO/CD11a/CD27, such as CD45RA, CCR7, and IL-7Rα. Should the pyrene-treated, 
costimulated T cells continue to express naïve markers, it may be interesting to assess the 
proliferative response of these cells to IL-7, a cytokine that is essential for naïve T cell 
homeostatic proliferation.  
 Here we have suggested that proliferation and differentiation of human naïve CD4+ T 
cells was not strongly influenced by BPA treatment but pyrene may have enhanced proliferation 
while inhibiting effector and memory differentiation during costimulation. Further investigation 
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Chapter 3. Human naïve CD4+ T cells isolated using EasySep do not stimulate comparably 
to those isolated using StemSep 
 
Introduction 
Prior to 2015, we routinely isolated human naïve CD4+ T cells from peripheral blood 
using the StemSep immunomagnetic negative selection kit, at which point StemCell approached 
us and indicated they planned to discontinue the StemSep kit we were using in favor of their new 
EasySep kit. 
StemSep. StemSep (StemCell, cat#14155) labels non-naïve, non-CD4+ cells with 
tetrameric selection antibodies (see Figure 3.1). One antibody in each tetramer binds to a 
specific protein that is found only on non-naïve cells, (see Table 3.1 for list of selection Abs) 
while the other antibody in the tetramer binds to dextran. The tetramer-labeled cells are then 
mixed with dextran-coated magnetic particles, and the anti-dextran antibody binds to the dextran 
coating the magnetic particles. Next, the cell-tetramer-particle complexes are applied to a 
column. The column consists of stacked mesh layers made of alternating nonmagnetic and 
magnetic stainless steel inside a syringe barrel, which is suspended in a magnetic field. The 
labeled cells are retained by the magnetic field in the column, while the untouched naïve CD4+ T 
cells pass through the column and are collected for downstream experimental use.  
EasySep. The newer kit, EasySep (StemCell cat#19155), similarly labels non-naïve, non-
CD4+ T cells using negative selection tetrameric antibody complexes in which one antibody 
targets a non-naïve cell for removal (see Table 3.1 for list of selection Abs) and the other 








Figure 3.1. Tetrameric antibody complex used in StemSep and EasySep isolations. 
Antibody tetramers consisting of a mouse IgG1 anti-cell antibody (light blue) linked to an anti-
dextran mouse IgG1 antibody (red) by two anti-mouse IgG1 Fc antibodies (green) are used to 
bind the target cell (dark blue) to the dextran-coated magnetic beads (purple), facilitating 




the cocktail differ considerably from those in the StemSep cocktail. Dextran-coated magnetic 
particles are added to the suspension and incubated to allow the anti-dextran antibodies to bind to 
the dextran-coated particles. The labeled cell suspension is placed in a strong magnetic field, and 
the labeled cells are retained in the magnetic field while the unlabeled, naïve cells are gently 
poured off. No column is employed in the EasySep isolation.  
Magnetic particles. In addition to the divergent composition of the negative selection 
antibody cocktails in the StemSep and EasySep kits, the magnetic beads are also dissimilar. Both 
kits employ superparamagnetic iron oxide (Fe3O4) particles coated with dextran. However, the 
StemSep magnetic particles (“magnetic colloid”) are 50-100 nm in diameter (1), and they are 
suspended in saline. The EasySep magnetic particles (“magnetic nanoparticles”) are 150-450 nm 
in diameter (1) and are suspended in water. The increased size of the EasySep particles is 
necessitated by the column-free isolation method. There may be further proprietary differences 
between the two types of magnetic beads of which we are unaware. As such, it is possible that 
the differences between the StemSep and EasySep magnetic particles could contribute to our 
observed differences in the differentiation of StemSep and EasySep naïve T cells.  
Antibody cocktails. Both StemSep and EasySep kits contain selection antibodies to 
CD45RO, CD8, CD14, CD16, CD19, CD56, and glycophorin A. However, EasySep has 
additional selection antibodies against CD20, CD25, CD36, CD61, CD66b, CD123, HLA-DR, 
and TCRγ/δ. Therefore, it is likely that one of more of the additional antibodies in the EasySep 
negative selection cocktail could contribute to the functional differences we have observed in the 






Table 3.1. Negative selection antibodies contained in StemCell’s StemSep and EasySep human 
naïve CD4+ T cell isolation kits indicated with “Y”s. 
  
Ab target Common name/cell target StemSep EasySep 
CD45RO Leukocyte common Ag (differentiated lymphocytes) Y Y 
CD8 TCR (MHC I) co-receptor (cytotoxic Ts, NKs, DCs) Y Y 
CD14 PAMP co-receptor for LPS (innate cells) Y Y 
CD16 low affinity IgG FcR (NK cells, PMNs, MΦ) Y Y 
CD19 B lymphocyte surface Ag B4 (BCR co-receptor, all B 
cells except plasma cells) 
Y Y 
CD20 B lymphocyte Ag CD20 (all stages of B cell 
development except initial and final stages) 
 Y 
CD25 IL-2Rα (activated lymphocytes)  Y 
CD36 Platelet glycoprotein 4 (platelets, monocytes, RBCs)  Y 
CD56 NCAM (NK cells) Y Y 
CD61 β3 integrin (platelets)  Y 
CD66b CEACAM-8 (granulocytes)  Y 
CD123 IL-3Rα (myeloid cells)  Y 
TCR γ/δ γ/δ T cells  Y 
HLA-DR MHC II (non-naïve)  Y 
CD235 Glycophorin A (RBCs) Y Y 
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CD20. CD20 refers to the B lymphocyte antigen CD20 protein, which is primarily found 
on B cells at all stages of development except the initial and final stages. Inclusion of the CD20 
antibody in the EasySep selection cocktail is most likely intended to further target B cells for 
removal, although the CD19 antibody found in both EasySep and StemSep is also intended to 
target B cells. However, CD20-expressing T cells have been detected in humans, both in a 
peripheral T cell lymphoma (2) as well as in healthy individuals, where CD3+ CD20+ T cells 
were found to make up 3-5% of the peripheral T cells in the blood (3). It is not known if there is 
a population of naïve T cells that expresses CD20. 
 CD25. The common name of CD25 is IL-2 receptor α-subunit. CD25 alone cannot 
transduce a signal into the cell upon ligand binding, but when complexed with IL-2Rβ and γc 
forms the high affinity IL-2 receptor. Among the pleiotropic effects of IL-2 signaling are T and 
B cell growth and expansion, induction of antibody production, and promotion of natural killer 
cell activity and activation-induced cell death.  The ostensible purpose of anti-CD25 in the 
EasySep negative selection cocktail is to remove activated T cells, as CD25 is commonly said to 
be expressed on activated T cells. CD25 is also expressed on Tregs and on most resting CD4+ 
memory cells. However, a study recently found a population of CD4+ CD45RA+ naïve T cells 
which express CD25 in the peripheral blood of adult humans (4). The size of the CD25+ subset 
of naïve T cells increased with age, reaching approximately 20% of the naïve T cell population 
by age 40 (5). This suggests that the addition of the CD25 antibody to the EasySep selection 
cocktail could potentially remove a not-inconsiderable subset of naïve T cells from the 




 CD36. CD36 is a widely expressed membrane glycoprotein. In the blood, CD36 has been 
shown to be expressed on platelets, monocytes, macrophages, dendritic cells, and erythroid 
precursors. CD36 is a receptor for thrombospondin-1 in addition to being a scavenger receptor. 
CD36 binds lipids and lipoproteins from bacterial cell walls, fungal β-glucans, and Plasmodium 
falciparum-infected erythrocytes (6). Additionally, CD36 can recognize and internalize oxidized 
low-density lipoprotein, which in macrophages promotes the formation of proatherogenic foam 
cells (7-8). The CD36 antibody included in the EasySep negative selection cocktail is likely 
intended to target monocytes and macrophages as CD36 was originally identified as a 
monocyte/macrophage marker (9). Expression of CD36 on T cells, particularly naïve T cells, has 
not been determined.  
 CD61. CD61 is also known as β3 integrin, which is thought to be a marker for 
megakaryocytes and platelets. It is not known whether human T cells express CD61, but CD61 
has been reported on the surface of canine peripheral blood lymphocytes (10). Since both 
EasySep and StemSep kits were designed for use with peripheral blood mononuclear cells 
(PBMCs) as the input, there should be few if any residual platelets in the starting cell population 
prior to StemSep or EasySep isolation. As such, inclusion of the CD61 antibody in the negative 
selection cocktail seems superfluous, assuming the intended target cell is indeed the platelet. 
 CD66b. CD66b is also referred to as CD67 and carcinoembryonic antigen related cell 
adhesion molecule 8 (CEACAM-8). CD66b is a member of the immunoglobulin super family. It 
is used to identify colorectal carcinomas but is also expressed in healthy tissues. CD66b is 
sometimes used as a marker of granulocyte activation, most frequently in neutrophils but it is 
also expressed on eosinophils (11). Again, because the starting cell population is PBMCs, there 
should be very few (if any) granulocytes present prior to the negative selection procedure. 
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Therefore, as with the CD61 antibody, the presence of anti-CD66b antibody in the selection 
cocktail for the purpose of removing granulocytes seems potentially gratuitous. 
 CD123. CD123 is the IL-3 receptor α-chain. CD123 must form a heterodimer with the 
cytokine common receptor β-chain to transduce signals. IL-3 produced by activated T cells as 
well as monocytes/macrophages, and it induces multipotent hematopoietic stem cells to 
differentiate into myeloid progenitors and activates basophils. CD123 is expressed on 
hematopoietic stem cells, basophils, acute myeloid leukemia cells, and T and B cell acute 
lymphoid leukemia cells (12). CD123 is also expressed on total CD4+ T cells from healthy 
donors and is upregulated on these cells when costimulated through CD28 (13). It is not known 
whether human naïve T cells express CD123. 
 HLA-DR. HLA-DR (human leukocyte antigen-DR isotype) is an isotype of the major 
histocompatibility complex class II receptor, which presents short peptide antigens to the T cell 
receptor. HLA-DR is expressed on antigen presenting cells as well as peripheral T cells. 
Expression of HLA-DR has come into common use as a marker of T cell activation. However, 
one study found that only 23% of HLA-DR+ CD4+ T cells co-expressed CD25 (IL-2Rα), which 
is considered a classic T cell activation marker (14), suggesting that use of HLA-DR expression 
alone as an index of T cell activation may warrant reconsideration. The expression of HLA-DR 
in T cell subsets has not been established, including naïve T cells.  
 TCRγδ. TCRγδ refers to the T cell receptor composed of the γ and δ subunits. Most T 
cells in the blood express TCRαβ, which recognizes peptide antigens presented in MHC class II. 
However, a population of T cells express TCRγδ, which recognizes lipid antigens presented in 
CD1. The majority of T cells found in the skin are TCRγδ+, but less than 5% of T cells in the 
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blood express γδ (15). As such, the number of γδ T cells in the PBMC population is expected to 
be very small, nevertheless the TCRγδ selection antibody is intended to target them for removal. 
 This chapter. This chapter will compare the naïve CD4+ T cells isolated using StemSep 
and EasySep with respect to viability, proliferation, and differentiation. We will also attempt to 
identify components of EasySep that are responsible for the observed differences between the 
populations isolated by the two kits.   
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Materials and methods 
Antibodies and reagents 
 Anti-CD3 (clone OKT3) was purchased from eBioscience (San Diego, CA), anti-CD28 
(clone CD28.2) was purchased from BioLegend (San Diego, CA), and anti-ICAM-1 (clone R6.5) 
was purchased from BioXCell (West Lebanon, NH). Annexin V-PE and 7-Amino-Actinomycin 
D (7AAD) were purchased from BD Pharmingen (San Jose, CA). Anti-CD11a-FITC (clone 
MEM-25) was purchased from Novus Biologicals (Littleton, CO), anti-CD27-PE (clone O323) 
was purchased from eBioscience (San Diego, CA), and anti-CD45RO-PerCP (clone UCHL1) 
was purchased from Invitrogen (Camarillo, CA).  
 
Cell purification 
 Heparinized peripheral whole blood (240 ml) was collected from healthy volunteer 
donors on three separate occasions at least 8 weeks apart and diluted two parts blood into one 
part sterile TC-PBS (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 9.6 mM Na2HPO4, 0.7 mM 
CaCl2, 0.5 mM MgCl2, and 10 mM glucose, pH 7.4) + 2% FBS + 1% penicillin/streptomycin. 
The PBMC layer was separated using Ficoll density gradient centrifugation as we have 
previously reported (16-17), collected by pipette, washed in TC-PBS to remove residual Ficoll 
and platelets, and cells were counted using a hemocytometer. The PBMC from one blood draw 
per donor were further purified to naïve CD4+ T cells using the StemSep kit (cat#14155; 
StemCell, Vancouver, BC, Canada) according to the manufacturer. The PBMC from the second 
blood draw from each donor was purified to naïve CD4+ T cells using the EasySep kit 
(cat#19155; StemCell, Vancouver, BC, Canada) according to the manufacturer.  
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In attempt to identify problematic components of the EasySep kit, we divided PBMC 
from one donor into three equal aliquots. We isolated naïve CD4+ T cells from one aliquot with 
the standard StemSep kit according to the manufacturer (StemSep selection cocktail and 
StemSep magnetic beads with column). The second aliquot was purified to CD4+ naïve T cells 
using the StemSep selection cocktail and StemSep magnetic beads and column but with 100 μl 
CD25 antibody tetramer (from Human CD25 Positive Selection kit cat#18231; StemCell, 
Cambridge, MA) added to the StemSep selection cocktail per the CD25+ deletion protocol in the 
CD25 Positive Selection kit tech sheet. The third aliquot was purified to naïve CD4+ T cells 
using StemSep selection cocktail and EasySep beads (50 μl per EasySep tech sheet) and a 
column. 
Purity was immediately assessed for each isolation by staining for CD11a, CD27, and 
CD45RO and analyzing by flow cytometry, gating on CD11a+ CD27lo CD45RO(-) population. 
 
Cell stimulation 
 Stimulating antibodies were diluted in sterile PBS to titrated lowest effective 
concentration. OKT3 (anti-CD3) was used at 1 μg/ml with either CD28.2 (anti-CD28) at 2 μg/ml 
or R6.5 (ICAM-1) at 10 μg/ml. Antibody solutions were added to 96-well tissue culture-treated 
plates (TPP, Switzerland) and incubated for 2 hours at 37°C or overnight at 4°C. Wells were then 
washed 3X with sterile PBS to remove any unbound antibody. Cells were added to the wells at 
1.5×106 cells/ml in RPMI 1640 (CellGro, Corning, NY) supplemented with 10% heat-inactivated 
FBS (Atlanta Biologicals, Atlanta, GA) 50 IU/ml penicillin/50 μg/ml streptomycin (CellGro), 





 Cells were removed from the tissue culture plate by gentle pipetting. Cell proliferation 
was measured by CFSE dilution as previously described (16). Cells were labeled prior to 
stimulation using 2.5 μM 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE: 
Molecular Probes; Eugene, OR) from 5 mM stock solution in DMSO for 7 minutes at 37°C in 
serum-free RPMI 1640. For effector/memory stain, cells were blocked with 0.5% BSA in PBS, 
stained with CD11a-FITC, CD27-PE, and CD45RO-PerCP for 1 hour on ice in the dark, and 
washed once in cold PBS. For cell death stain, cells were washed twice in cold PBS, stained in 
Annexin V binding buffer (0.01 M HEPES pH 7.4, 0.14 M NaCl, 2.5 M CaCl2) with Annexin V-
PE and 7AAD, and washed once in Annexin V binding buffer. Stained cells were then analyzed 
using the Accuri C6 flow cytometer with CFlow software (Accuri Cytometers). Single color 









Table 3.2 EasySep isolation yields fewer human naïve CD4+ T cells than StemSep isolation. 
240 mL whole heparinized blood was collected from each volunteer donor on three separate 
occasions at least 8 weeks apart. PBMC were obtained from blood by Ficoll density gradient 
centrifugation and naïve CD4+ T cells were isolated using either StemSep or EasySep negative 
selection kits. Yields are given in 106 cells and percent yield was calculated by dividing total 
number of naïve cells obtained by number of starting PBMC. Purity of the naïve cells was 98% 







The purified StemSep and EasySep naïve CD4+ T cells appeared phenotypically similar 
by CD45RO/CD27/CD11a immediately after isolation. The purity by these three markers was 
comparable (~98% CD45RO(-) CD27+ CD11a(-) for both StemSep and EasySep) though the yield 
of the EasySep naïve cells was somewhat lower than that of the StemSep naives when compared 
to the same blood donor (Table 3.2). 
 We also tested the StemSep and EasySep naïve T cells in our in vitro differentiation 
system. This system uses plate-bound antibodies to stimulate specific cell surface receptors 
mimicking cell-cell contact occurring during costimulation in vivo. We stimulated the cells 
through CD3+CD28, the T cell receptor and the classic T cell costimulatory receptor, as well as 
CD3+ICAM-1, the T cell receptor and an alternate costimulatory molecule, intercellular 
adhesion molecule-1. After 7 days of costimulation, we evaluated the results. 
 
Costimulated EasySep naïve T cells do not appear to clump comparably to costimulated 
StemSep naïve T cells. 
Microscopic observation of the T cells in the wells of the tissue culture plate after 7 days 
of costimulation rsuggested some differences among the cells isolated by the two methods. The 
CD3+ICAM-1 costimulated StemSep cells appeared densely distributed across the field with 
many large clumps present (Figure 3.2, top image). As we have previously published, clumping 
of T cells is an indication of activation (17). Similarly, many large cell clumps were present in 
CD3+CD28 stimulated StemSep T cells (Figure 3.2, center image). Conversely, no cell 







Figure 3.2 EasySep naïve T cells do not clump comparably to StemSep naïve T cells from 
the same donor during costimulation. Naïve CD4+ T cells were purified from peripheral blood 
using either StemSep or EasySep and stimulated for 7 days through CD3+ICAM-1 or 




densely distributed in the well (Figure 3.2, bottom image). The CD3+CD28 stimulated EasySep 
cells resembled the CD3+ICAM-1 EasySep cells (data not shown). 
 
EasySep naïve T cells had altered forward scatter versus side scatter flow cytometry 
profiles compared to StemSep naïve T cells after 7 days of costimulation. 
We found that the StemSep naïve T cells differed from the EasySep naïve T cells after 7 
days of costimulation by their flow cytometry forward scatter versus side scatter profiles (Figure 
3.3). Forward scatter indicates the size of the particle moving past the detector while the side 
scatter shows granularity. The location of a particle in the forward scatter versus side scatter plot 
can be used to identify the type of particle. Intact, live T cells generally appear in the area 
enclosed by the green gates (Figure 3.3), while the activated and dividing blast cell population is 
shown in the blue gates and the dead and dying cell population is found in the red gates. The blue 
blast population was considerably reduced for both costimulations and both donors with EasySep 
compared to StemSep, and the red dead and dying cell population was likewise increased.  
 
Cell death was dramatically increased for EasySep naïve T cells costimulated for 7 days 
compared to costimulated StemSep naïve T cells. 
The amount of cell death of EasySep naïve T cells was different from that of StemSep 
naïve T cells after 7 days of costimulation. The percentage of dead (Annexin V+ 7AAD+) cells in 
the ICAM-1 costimulations was 1.0-9.3% for StemSep naïve cells, while the percentage of dead 








Figure 3.3. Forward scatter versus side scatter profiles showed that EasySep naïve T cells 
had fewer blasts and more cell death compared to StemSep naïve T cells after 7 days of 
costimulation through ICAM-1 or CD28. Flow cytometry forward scatter (FSC) versus side 
scatter (SSC) plot comparing the StemSep naïve T cells (left) with the EasySep naïve T cells 
(right) of the same blood donor after 7 days of costimulation through CD3+ICAM-1 (left side 
plots) or CD3+CD28 (right side plots). The red gate and red percentage indicate the dead and 
dying cell population. The green gate and green percentage show the live cell population. The 









Figure 3.4 Cell death was dramatically increased in EasySep naïve T cells compared to 
StemSep naïve T cells from the same donor. Naïve T cells were purified from peripheral blood 
using either StemSep or EasySep and stimulated through CD3+ICAM-1 or CD3+CD28 for 7 
days. Cells were then stained using Annexin V and 7AAD and analyzed by flow cytometry. 
Dead cells are Annexin V+ 7AAD+ and located in the UR quadrant, with the percentage of dead 




costimulated StemSep naïve cells was 2.3-21.8% while the percentage of dead CD28-
costimulated EasySep naïve T cells was 24.9-85.9% (Figure 3.4).  
 
EasySep naïve T cells had dramatically reduced effector and memory cell differentiation 
compared to StemSep naïve T cells. 
 We compared the capacity of EasySep naïve T cells to differentiate into effector and 
memory cells with that of StemSep naïve T cells using flow cytometry. We gated on the 
CD45RO+ (differentiated) cell population then assessed CD11a and CD27 expression to measure 
the effector and memory populations. For both donors and both ICAM-1 and CD28 
costimulations, we observed a marked reduction in effector and memory cell populations in the 
EasySep naïve T cells. In the ICAM-1 costimulations, there were 33.5-45.5% effector and 5.4-
18.6% memory for the StemSep naïve cells, while for the EasySep naïve cells there were 10.8-
17.8% effector and 0-0.3% memory (Figure 3.5A). In the CD28 costimulations, there were 74.0-
76.4% effectors and 8.3-12.8% memory for the StemSep naïve cells, and for the EasySep naïve 
cells there were 18.6-23.4% effectors and 2.5-3.3% memory (Figure 3.5A). Number of effector 
and memory cells is represented graphically in Figure 3.5B, with the bar indicating the mean. 
The cell numbers differed somewhat among the two donors as is commonly observed for 
primary human cells, but a strong visual trend in reduction of cell number for both EasySep 









Figure 3.5 EasySep naïve T cells showed markedly reduced effector and memory cell 
differentiation compared to StemSep naïve T cells from the same donor. Naïve T cells were 
purified from peripheral blood using either StemSep (left) or EasySep (right) and stimulated for 
7 days through either CD3+ICAM-1 (left plot) or CD3+CD28 (right plot) then analyzed by flow 
cytometry. A. CD11a versus CD27 dot plots gated on CD45RO+ population with effector cells in 
the UR quadrant and memory cells in the LR quadrant. Percentage of population is given in bold 
while cell number is in parentheses. B. Number of effector cells (CD45RO+ CD11a+ CD27+) 
shown in the left-hand graph for StemSep and EasySep. Number of memory cells (CD45RO+ 





Inclusion of CD25 antibody in the selection cocktail and EasySep magnetic beads may 
both have reduced effector cell differentiation. 
Having ascertained that naïve T cells isolated using EasySep have reduced effector and 
memory cell differentiation as well as increased cell death, we sought to identify which specific 
components of the EasySep kit were responsible for these results. Because the literature 
indicated that CD25 was indeed weakly expressed on naïve T cells (4-5), we hypothesized that 
removal of the CD25+ population via the CD25 antibody tetramer included in the EasySep 
negative selection cocktail could potentially account for some of the observed differences among 
EasySep and StemSep naïve T cells.  We therefore added CD25 antibody tetramer to the 
StemSep negative selection cocktail and used StemSep magnetic beads to isolate naïve T cells. 
We also wanted to verify that the EasySep beads themselves were not causing any of the 
observed differences among StemSep and EasySep naïve T cells, so we performed a naïve T cell 
isolation using StemSep negative selection cocktail with EasySep beads and a column to 
facilitate this comparison. 
Preliminary results (n=1) suggested that addition of the CD25 tetramer reduced effector 
cell differentiation for ICAM-1 and CD28 costimulations, while the use of EasySep beads with 
the StemSep cocktail also resulted in reduced effectors (Figure 3.6). In the ICAM-1 
costimulation (Figure 3.6, top row), there were 33,286 effector cells for the standard StemSep 
isolation, but there were only 12,273 effectors for StemSep+CD25 isolation and 1,679 effectors 
for the EasySep beads isolation. In the CD28 costimulation (Figure 3.6, bottom row), there were 









Figure 3.6 Addition of CD25 antibody tetramer to negative selection cocktail or use of 
EasySep beads reduced differentiation of effector cells. Naïve T cells were purified from 
peripheral blood using standard StemSep isolation (StemSep antibody cocktail with StemSep 
magnetic beads; left); StemSep isolation with the addition of CD25 antibody tetramer to the 
antibody cocktail and StemSep magnetic beads (center); or StemSep antibody cocktail with 
EasySep magnetic beads (right). Naïve T cells from each isolation were stimulated through 
CD3+ICAM-1 (top row) or CD3+CD28 (bottom row) for 7 days before analysis by flow 
cytometry. All plots are gated on the CD45RO+ population with effector cells shown in the UR 
quadrant (CD11a+ CD27+) and memory cells in the LR quadrant (CD11a+ CD27lo/(-)). Percentage 




were 16,962 effectors and for the EasySep beads isolation there were 6,278 effectors. There were 
also fewer overall CD45RO+ cells in the StemSep+CD25 and EasySep beads isolations. 
 
Addition of CD25 antibody tetramer to selection cocktail or use of EasySep magnetic 
beads may have increased cell death during costimulation. 
We measured cell death on Day 7 of ICAM-1 or CD28 costimulation using flow 
cytometry with Annexin V and 7AAD staining. Our preliminary results (n=1) suggested that for 
ICAM-1 costimulation, there was 7.7% dead cells (Annexin V+ 7AAD+) for the standard 
isolation using StemSep antibody selection cocktail and StemSep magnetic beads; however, for 
StemSep selection cocktail + CD25 antibody tetramer with StemSep beads there was 17.3% dead 
cells, and for isolation with StemSep cocktail and EasySep beads there was 35.6% dead cells 
(Figure 3.7, top row). Likewise, for CD28 costimulation, there was 3.5% dead cells for the 
standard StemSep isolation; however, for StemSep selection cocktail + CD25 antibody tetramer 
with StemSep beads there was 15.1% dead cells, and for isolation with StemSep cocktail and 










Figure 3.7 Addition of CD25 antibody tetramer to negative selection cocktail or use of 
EasySep beads increased cell death. Naïve T cells were purified from peripheral blood using 
StemSep antibody cocktail with StemSep magnetic beads (left), StemSep antibody cocktail with 
CD25 tetramer and StemSep magnetic beads (center), or StemSep antibody cocktail with 
EasySep magnetic beads (right). Naïve T cells from each isolation were stimulated through 
CD3+ICAM-1 (top row) or CD3+CD28 (bottom row) for 7 days before analysis by flow 









 We have used StemSep human naïve CD4+ T cell negative selection kits to isolate 
functional cells from peripheral blood for more than 15 years. As we have previously 
demonstrated (references 18-20 as well as the dissertations of Drs. Jake Kohlmeier, Kelli 
Williams, Abby Dotson, and Amy Newton), naïve T cells isolated in this way activate, 
proliferate, differentiate into effector and memory cells of various T cell subsets, and produce 
cytokines in response to costimulation through CD28, ICAM-1, LFA-1, and CTLA-4 without 
addition of exogenous cytokines. However, StemCell discontinued this kit and replaced it with 
EasySep, which is different from the StemSep kit in that it is column-free, employs a selection 
cocktail with antibodies against several additional cell targets, and utilizes larger magnetic beads. 
 We compared the StemSep and EasySep kits by performing differentiation experiments 
using cells isolated from the same blood donor. Our initial finding was that yields of naïve CD4+ 
T cells were reduced for EasySep isolations even though the number of PBMC obtained per 
donor for each experiment was comparable as was the purity of the resulting naïve cells. This 
reduction in cell yield was unsurprising. With the additional selection antibodies in EasySep, one 
would expect more cells to be targeted for removal.  
We observed less activation (indicated by cell clumping during microscopic observation) during 
costimulation and fewer blasts, with an increase in the dead cell population for EasySep. In 
agreement with these findings, there was also a large increase in cell death and reduced effector 
and memory cell differentiation for both costimulations in the EasySep naïve cells.  
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Naïve T cells isolated using EasySep did not differentiate comparably during 
costimulation and a large percentage of these cells were dead by Day 7. We hypothesized that 
the additional selection antibodies in EasySep may remove a subset of naïve T cells which are 
essential for differentiation and cell survival or that some component of EasySep is toxic to naïve 
T cells. Naïve T cells are a relatively recently discovered population of cells, the properties and 
surface markers of which are still being elucidated, so it is possible that one of the selection 
antibodies that was intended to target a non-naïve cell for removal instead binds to a naïve cell 
and removes it, since expression of that particular protein had not yet been determined for naïve 
T cells. 
The selection cocktail of EasySep contains CD25 antibody tetramer, while the StemSep 
cocktail does not. CD25 is the IL-2 receptor α chain, and IL-2 is a critical T cell cytokine 
promoting growth and differentiation. Recent work indicates CD25 is weakly expressed on naïve 
T cells (4-5). Therefore, it is possible that the CD25 tetramer could remove the CD25+ 
population of naïve T cells. Further, removing this population of cells capable of responding to 
IL-2 could potentially perturb naïve T cell differentiation. Further, our in vitro differentiation 
system, which relies on stimulation of cell surface receptors by antibodies instead of exogenous 
cytokines, may be particularly vulnerable to detrimental effects caused by loss of the CD25+ 
population. Our preliminary results suggested that removal of the CD25+ population of naïve T 
cells inhibited effector cell differentiation and promoted cell death. This result also suggested a 
significant role for CD25/IL-2 in naïve T cell differentiation, even for naïve T cells that are 
CD25(-). 
The only published differences between the StemSep magnetic beads and the EasySep 
magnetic beads are their sizes (50-100 nm diameter for StemSep versus 150-450 nm for 
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EasySep) and the solution in which they are suspended (saline for StemSep versus sterile water 
for EasySep). As such, we thought it unlikely that the magnetic beads themselves would make a 
noticeable difference in differentiation outcome but, in the interest of thoroughness, decided to 
test this assumption. Our initial assay found that differentiation of effector cells was greatly 
reduced and cell death was increased for naïve T cells isolated using the StemSep selection 
cocktail and the EasySep beads compared to naïve T cells isolated using StemSep cocktail and 
StemSep beads. 
This result was surprising because the beads themselves are not intended to directly 
interact with the naïve T cells since the isolation is based on negative selection. Further, the cell 
suspension was only incubated with the magnetic beads for 15 minutes. Observing marked 
differences in effector cell number and dead cell number 7 days later was therefore unexpected. 
We hypothesize that there may have been additional components of the magnetic bead 
suspension beyond water and the beads that were proprietary and are somewhat toxic to naïve T 
cells.  
We observed that naïve CD4+ T cells isolated using EasySep did not activate or 
differentiate comparably to those isolated using StemSep. Additionally, inclusion of CD25 
antibody tetramer in the EasySep selection cocktail as well as the EasySep magnetic beads both 
may have played a role in the loss of differentiation but neither component was fully responsible 
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Chapter 4. Summary: Development and testing peptides corresponding to ICAM-1 and 
LFA-1 as a potential therapy for equine recurrent uveitis 
 
 This project was undertaken as a collaboration with Dr. Abby Dotson and Dr. Susan Keil, 
veterinary ophthalmologist.  
 Equine recurrent uveitis (ERU) is a progressive inflammatory disease of the eye which 
affects 15% of horses and can lead to blindness. ERU has many characteristics of autoimmune 
disease. Current therapies for autoimmune conditions are generally immunosuppressive, 
blocking the activation of not only self-reactive immune cells but also immune cells that protect 
the organism from infection. Our lab has previously developed therapeutic peptides 
corresponding to the contact domains of ICAM-1 and LFA-1, inhibiting the interaction of these 
two receptors and inactivating only self-reactive immune cells and leaving normal, protective 
immune cells fully functioning. We have demonstrated the efficacy of these peptides in blocking 
human T cell activation during in vitro mixed lymphocyte reactions (MLRs) as well as protecting 
against autoimmune disease in murine models of rheumatoid arthritis and emphysema.  
 Here, we designed cyclic peptides corresponding to the equine sequences of ICAM-1 and 
LFA-1. We demonstrated the ability of these peptides to dose-dependently inhibit activation of 
equine T cells measured by homotypic adhesion assays using mitogen-treated total T cells 
purified from the peripheral blood of healthy horses as well as horses with ERU. Next, we 
measured proliferation of equine T cells treated with peptides during MLR. Surprisingly, we 
observed that T cell proliferation dose-dependently increased during treatment with both ICAM-
1 and LFA-1 peptides together. Further studies suggested that treatment with the equine ICAM-1 
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peptide alone promoted T cell proliferation beyond that induced by phytohemagglutinin, but 
treatment with the equine LFA-1 peptide did not affect proliferation.  
 This suggested that the ICAM-1 peptide was somehow stimulating the T cells, potentially 
by interacting with cell surface ICAM-1. These data suggested that the equine ICAM-1 peptide 
would not be useful as a therapy for autoimmunity but the peptide may have other potential uses. 
Further, redesign of this peptide could remove its stimulatory ability, allowing its potential use 
for treatment of autoimmunity.  
 We also attempted to develop an antigen recall assay that could potentially be used to 
help diagnose ERU. In this assay, peripheral blood mononuclear cells (PBMCs) from a horse 
suspected of having ERU would be treated with an equine eye-specific protein and proliferation 
response to this antigen would be evaluated. Cells from horses that had ERU would be expected 
to proliferate in response to eye antigen, while cells from healthy horses would not proliferate. 
We tested several antigens on PBMCs from both healthy and ERU horses but proliferation was 
comparable to the unstimulated control for all antigens at all concentrations tested. One potential 
explanation for the failure of the antigens to stimulate equine cells could be that the eye antigens 
were purified human proteins, since there were no commercially available equine proteins 
available at the time. It is possible that the human antigens were dissimilar enough from the 
equine antigens that they failed to elicit a response from the equine immune cells.  
Another alternative is that there were insufficient antigen-presenting cells in our PBMCs. 
We had purified PBMCs from equine blood using a standard density gradient centrifugation 
protocol with standard Ficoll of 1.077 g/ml density (optimal density for human PBMC isolation). 
However, immediate post-isolation staining of the PBMCs for CD3, the T cell receptor, showed 
94 
 
that the PBMCs were 95-98% CD3+, suggesting an unusually low percentage of antigen-
presenting cells for a PBMC preparation. A not-inconsiderable quantity of literature searching 
indicated that the optimal density of the density centrifugation reagent was 1.068 g/ml for equine 
PBMCs. The next step towards developing the ERU antigen recall assay would be to isolate 
PBMCs using 1.068 g/ml density Ficoll as well as testing purified equine ocular antigens instead 




Chapter 5. Summary: Associated proteins of the ICAM-1 signaling complex in human T 
cells and comparison with the CD28 signaling complex 
 
 Previous work in our laboratory by Dr. Chintana Chirathaworn and Dr. Jake Kohlmeier 
demonstrated that stimulating T cells through ICAM-1 induces phosphorylation of several 
proteins and can serve as a second signal for T cell activation and differentiation. Costimulation 
of human naïve CD4+ T cells through ICAM-1 promotes differentiation into T helper 1 and T 
regulatory cells but not T helper 2 cells, while costimulation through CD28 promotes 
differentiation into T helper 1 and T helper 2 cells but not T regulatory cells. These alternative 
differentiation outcomes imply that the signaling induced by ICAM-1 stimulation is not the same 
as the signaling induced by CD28 stimulation. This work is part of a long term, ongoing effort by 
our laboratory to understand ICAM-1 signaling in T cells. 
 Dr. Chirathaworn showed that in Molt3, an ICAM-1+ T cell leukemia, ICAM-1 
crosslinking induced association with cdc2 and Lck kinases and also showed a constitutive 
association with ERK2. Her data also supported induced phosphorylation of cdc2 on ICAM-1 
crosslinking which correlated with inactivation of cdc2. Preliminary data from Dr. Brian Wick 
indicated that ERK2 may be phosphorylated on ICAM-1 stimulation 
 We verified the surface expression of ICAM-1 on Molt3 T cells by flow cytometry. We 
also confirmed the work of Drs. Chirathaworn, Williams, and Wick in human T cell lines and 
primary T cells using co-immunoprecipitation assays. We demonstrated that ZAP-70 kinase 
became associated with ICAM-1 after 2 minutes of stimulation and leaving the complex by 6 
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minutes. We also found that the related Syk kinase may also be inducibly associated with ICAM-
1, which agrees with the work of other investigators in other non-immune cell types.  
 Our preliminary data indicated that ZAP-70 did not associate with CD28 on stimulation, 
unlike ICAM-1 stimulation. We also examined the association of ERK1/2 with CD28. We 
showed that ERK1/2 became associated with CD28 at 2-10 minutes of stimulation. Conversely, 
ERK2 only was constitutively associated with ICAM-1. Lck may be associated with CD28 at 2 
minutes of stimulation and then leaving the complex, similar to the kinetics of the association of 
Lck with ICAM-1.  
 We demonstrated that the ICAM-1 signaling complex in human T cells contains ZAP-70 





Chapter 6. Summary: Preliminary data comparing the ICAM-1 signaling protein complex 
in mouse and human T cells 
  
 Our lab has previously demonstrated that costimulation of human naïve CD4+ T cells 
through ICAM-1 promotes differentiation of T regulatory cells without addition of exogenous 
cytokines. The laboratory has previously patented an autologous T cell therapy for treatment of 
autoimmune disease based on this observation, in which naïve CD4+ T cells would be purified 
from the patient’s blood, costimulated through ICAM-1 to induce T regulatory cell 
differentiation, and then returned to the patient. Once the T regulatory cells have been 
reintroduced to the patient, they would circulate the body suppressing autoimmune 
inflammation. This therapy offers a significant advantage over current therapies for autoimmune 
conditions, which are globally immunosuppressive, leaving the patient vulnerable to infection. 
However, our proposed autologous T cell therapy would shut down autoimmune inflammation 
but leave the patient’s immune system able to respond appropriately to exogenous threats. The 
next step towards developing this idea as a therapy would entail a demonstration of its efficacy in 
a mouse model of autoimmunity. However, previous lab members have shown that murine T 
cells do not differentiate into T regulatory cells during ICAM-1 costimulation. As such, it was of 
interest to determine how the murine ICAM-1 signaling pathway diverges from the human 
pathway. 
 Due to the difficulty in obtaining primary mouse T cells in sufficient quantity for the 
proposed coimmunoprecipitation studies, we chose to use EL4, a murine T cell lymphoma. We 
first characterized our EL4 line using flow cytometry, showing that the cells were CD3+ CD4+ 
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CD11a+ ICAM-1+. Next, we verified the kinetics and ability of the mouse anti-ICAM-1 antibody 
to stimulate EL4 cells by crosslinking with a secondary antibody, finding that ICAM-1 
stimulation induced alterations in tyrosine phosphorylation of several proteins via western blot 
and induced increase in CD69 expression (a marker of T cell activation) over time by flow 
cytometry. Therefore, we concluded that our ICAM-1 antibody was inducing signaling events in 
the mouse T cells. Next, we titrated the ICAM-1 antibody to optimize conditions for ICAM-1 
immunoprecipitation. 
 Finally, we used ICAM-1 co-immunoprecipitation to look for proteins which associated 
with ICAM-1 during stimulation. Preliminary data suggested that Lck was inducibly associated 
with ICAM-1 upon stimulation, similar to our lab’s observations in human T cells. Likewise, 
cdc2 was associated with ICAM-1 at 2 minutes of stimulation then leaving the complex, as in 
human T cells. In contrast to our findings concerning the human ICAM-1 complex, in the murine 
ICAM-1 complex ZAP-70 was not present at any time point; nor were ERK1/2.  
 These preliminary results support our hypothesis that ICAM-1 signaling is different in 
mouse and human T cells.  
 
  
